公开(公告)号：US20160333072A1

公开(公告)日：2016-11-17

申请号：US15110111

申请日：2015-01-08

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Abraham RUTENBERG ,  Ronny UZANA ,  Michal LOTEM ,  Arthur MACHLENKIN ,  Galit EISENBERG ,  Tamar PERETZ-YABLONSKY ,  Shoshana FRANKENBURG ,  Roni ENGELSTEIN

IPC: C07K14/705 ,  A61K39/395 ,  C12N5/0783 ,  A61K39/39 ,  A61K35/17 ,  C07K16/28 ,  A61K45/06

CPC classification number: C07K14/70503 ,  A61K35/17 ,  A61K39/39 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/75 ,  C12N5/0638 ,  C12N2501/998

Abstract: Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

Abstract translation: 仅针对免疫治疗领域。 具体地，提供了用于体外和体内改善T细胞调节以及用于治疗癌症和其它病症的组合物和方法。 更具体地，本发明的实施方案涉及可溶性NTB-A多肽或其激动剂在治疗癌症患者中的用途，用于预防和治疗易感患者中的血细胞减少，以及用于离体制备改善的细胞组合物。

公开(公告)号：US20230078665A1

公开(公告)日：2023-03-16

申请号：US18054346

申请日：2022-11-10

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Abraham RUTENBERG ,  Ronny UZANA ,  Michal LOTEM ,  Arthur MACHLENKIN ,  Galit EISENBERG ,  Tamar PERETZ-YABLONSKY ,  Shoshana FRANKENBURG ,  Roni ENGELSTEIN

IPC: C07K14/705 ,  C12N5/0783 ,  A61K38/17 ,  A61K35/17 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

公开(公告)号：US20190330303A1

公开(公告)日：2019-10-31

申请号：US16417048

申请日：2019-05-20

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD

Inventor： Abraham RUTENBERG ,  Ronny UZANA ,  Michal LOTEM ,  Arthur MACHLENKIN ,  Galit EISENBERG ,  Tamar PERETZ-YABLONSKY ,  Shoshana FRANKENBURG ,  Roni ENGELSTEIN

IPC: C07K14/705 ,  A61K39/39 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  A61K35/17 ,  C12N5/0783

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.